Pegaptanib octasodium for the treatment of diabetic macular edema

Bibliography

• Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Report number 1. Arch Ophthalmol 1985;103:1796-806
   PubMed Web of Science ®Google Scholar
• Diabetic Retinopathy Clinical Research Network. Randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008;115:1447-59
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, VEGF inhibition study in ocular neovascularization clinical trial group. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med 2004;351:2805-16
   PubMed Web of Science ®Google Scholar
• Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann NY Acad Sci 2006;1082:151-71
   PubMed Web of Science ®Google Scholar
• Cunningham ET Jr, Adamis AP, Altaweel M, A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112:1747-57
   PubMed Web of Science ®Google Scholar
• Holz FG. Pfizer A5751013 Trial, A phase 2/3 randomized, controlled, double-masked, multi-center, comparative trial, in parallel groups, compares the safety and efficacy of intravitreous injections of 0.3 mg pegaptanib sodium (Macugen®), given as often as every 6 weeks for 2 years, to sham injections, in subjects with diabetic macular edema (DME). Data presented at the World Ophthalmology Congress, 9 June 2010, Berlin, Germany
   Google Scholar
• Ciulla TA, Amador AG. Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 2003;26:2653-64
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol 1999;14:223-32
   PubMedGoogle Scholar
• Gardner TW, Antonetti DA, Barber AJ, Diabetic retinopathy: more than meetsthe eye. Surv Ophthalmol 2002;47(Suppl 2):S253-62
   Google Scholar
• Lu M, Perez VL, Ma N, VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci 1999;40:1808-12
   PubMed Web of Science ®Google Scholar
• Barleon B, Sozzani S, Zhou D, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336-43
   PubMed Web of Science ®Google Scholar
• Wang J, Xu X, Elliott MH, Muller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes 2010;59:2297-305
   PubMed Web of Science ®Google Scholar
• Tolentino MJ, Miller JW, Gragoudas ES, Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 1996;103:1820-8
   PubMed Web of Science ®Google Scholar
• Cladwell RB, Bartoli M, Behzadian MA, Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev 2003;19:442-55
   Google Scholar
• Nashijima K, Ng Y-S, Zhong L, VEGF-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67
   Google Scholar
• Kamba T, Tam BY, Hashizume H, VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006;290:H560-76
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K, VEGF-164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 2003;44:215562
   Google Scholar
• Ishida S, Usui T, Yamashiro K, VEGF-164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483-9
   PubMed Web of Science ®Google Scholar
• Adamis AP, Ataweel M, Bressler NM, Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006;113:23-8
   PubMed Web of Science ®Google Scholar
• Peters S, Heiduschka P, Julien S, Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 2007;143:995-1002
   PubMed Web of Science ®Google Scholar
• Chung EJ, Roh MI, Kwon OW, Effects of macular ischemia on the outcome of intravitreal bevacizumab therapy for diabetic macular edema. Retina 2008;28:957-63
   PubMed Web of Science ®Google Scholar
• Salam A, DaCosta J, Sivaprasad S. Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol 2010;94:821-6
   Google Scholar
• Querques G, Bux AV, Martinelli D, Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 2009;87:623-30
   Google Scholar
• Querques G, Bux AV, Fusco AR, Pegaptanib sodium versus pegaptanib sodium combined with macular laser photocoagulation or laser alone for diabetic macular edema [article ID 672178]. J Ophthalmol 2009: published online 9 March 2010, doi:10.1155/2009/672178
   Google Scholar
• NeLM news service. Phase III study shows pegaptanib sodium improved vision over standard of care in patients with diabetic macular edema. 24 June 2010. Available from: http://www.nelm.nhs.uk/en/NeLM-Area/News/2010–June/24/Phase-III-study-shows-pegaptanib-sodium-improved-vision-over-standard-of-care-in-patients-with-diabetic-macular-oedema/?query=pegaptanib&rank=100 [Last accessed 1 December 2010]
   Google Scholar
• D'Amico DJ, Masonson HN, Patel M, ; VEGF inhibition study in ocular neovascularization (VISION) clinical trial group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001
   PubMed Web of Science ®Google Scholar
• Singerman LJ, Masonson H, Patel M, Pegaptanib sodium for neovascular age-related macular degeneration: third year safety results of the VEGF inhibition study in ocular neovascularization (VISION) trial. Br J Ophthalmol 2008;92:1606-11
   PubMed Web of Science ®Google Scholar
• Salz D, Prenner J, Cunningham ET Jr. Local complications of IV Anti-VEGF therapy. Rev Ophthalmol 2010;11:66-74
   Google Scholar
• Ciulla TA, Starr MB, Masket S. Bacterial endophthalmitis prophylaxis for cataract surgery. An evidence-based update. Ophthalmology 2002;109:13-24
   PubMed Web of Science ®Google Scholar
• Falkenstein IA, Chang L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (Avastin). Retina 2007;27:1044-7
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2010: published online 11 August 2010, doi:10.1136/bjo.2010.180729
   Google Scholar
• Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2007;143:1034-5
   PubMedGoogle Scholar
• Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930-4
   PubMed Web of Science ®Google Scholar
• Sniegowski M, Mandava N, Kahook MY. Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis. Open Ophthalmol J 2010;4:28-9
   PubMedGoogle Scholar
• Kahook MY, Liu L, Ruzycki P, High-molecular-weight aggregates in repackaged bevacizumab. Retina 2010;30:887-92
   PubMed Web of Science ®Google Scholar
• De Franciscis V, Esposito CL, Catuogno S, Aptamers as innovative diagnostic and therapeutic agents in the central nervous system. CNS Neurol Disord Drug Targets 2009;8:393-401
   Google Scholar
• Ladas ID, Karagiannis DA, Rouvas AA, Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2000 injections. Retina 2009;29:313-8
   PubMed Web of Science ®Google Scholar
• Wickremasinghe SS, Michalova K, Gilhotra J, Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 2008;115:1911-5
   PubMed Web of Science ®Google Scholar
• Mason JO, Wigton EH, Emond TL. Prevention of recurrent bevacizumab-induced intraocular inflammation [poster 408]. American Academy of Ophthalmology Annual Meeting, 16 – 19 October 2010, Chicago IL, USA
   Google Scholar
• Agawa T, Usui Y, Wakabayashi Y, Increased intraocular concentrations of various cytokines in AMD treated with intravitreal injection of bevacizumab [poster 219]. American Academy of Ophthalmology Annual Meeting, 16 – 19 October 2010, Chicago IL, USA
   Google Scholar
• Mansour AM, Bynoe LA, Welch JC, Retinal vascular events after intravitreal bevacizumab. Acta Ophthalmol 2010;88:730-5
   Google Scholar
• Shima C, Sakaguchi H, Gomi F, Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol 2008;86:372-6
   PubMed Web of Science ®Google Scholar
• Papadopoulou DN, Mendrinos E, Mangioris G, Intravitreal ranibizumab may induce retinal arteriolar vasoconstriction in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:1755-61
   PubMed Web of Science ®Google Scholar
• Soliman W, Vinten M, Sander B, Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema. Acta Ophthalmol 2008;86:365-71
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Snyder MR, Reid JM, Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9
   PubMed Web of Science ®Google Scholar
• Van Wijngaarden P, Coster DJ, Williams KA. Inhibitors of ocular neovascularization: promises and potential problems. JAMA 2005;293:1509-13
   PubMed Web of Science ®Google Scholar
• Yang JC, Haworth L, Sherry RM, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Eng J Med 2003;349:427-34
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA, Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006;113:1-12
   PubMedGoogle Scholar
• Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for macular degeneration. Arch Ophthalmol 2010;128:1273-9
   PubMed Web of Science ®Google Scholar
• Eyetech Announces Program to Develop Extended-Release Formulation of Macugen. Available from: http://www.bioportfolio.com/news/article/196415/Eyetech-Announces-Program-To-Develop-Extended-release-Formulation-Of-Macugen-r.html [Last accessed 30 November 2010]
   Google Scholar